HitIQ’s mouthguard has met World Rugby’s standards
Neurotech releases more positive data from Phase II/III clinical trial
Telix upgrades guidance
HitIQ’s mouthguard approved by World Rugby
HitIQ (ASX:HIQ), a leading provider of concussion management technologies, announced that it has met World Rugby‘s performance standards for instrumented mouthguards (IMGs).
This achievement allows HITIQ’s advanced mouthguard technology to be used in rugby union matches worldwide.
World Rugby has recently recognised the potential of instrumented mouthguard technology to improve player safety and has established new minimum standards for their use in rugby.
These specifications have been developed based on current best practice validity assessment methods, and expert consultation with engineers and biomechanists across four assessment criteria: Impact energy absorption (CE), Laboratory testing, On-field testing and Real-time performance.
Instrumented mouthguards are now required to meet the specifications relating to all four assessment criteria to be used at all levels and age grades of the game.
The real time performance assessment demonstrates a shift towards using impact data immediately during games.
This capability is crucial for enhancing player safety by facilitating immediate assessment of head injuries during matches, known as the Head Injury Assessment (HIA) process.
The World Rugby’s approval opens up substantial commercial opportunities for HitIQ within the expansive global rugby market, which comprises over 8 million registered players across 132 national federations.
HITIQ says it is now positioned to capitalise on this approval by actively pursuing and accelerating partnerships with rugby organisations worldwide.
“This validation demonstrates the quality and efficacy of our technology and positions us as a key player in the safety solutions market for rugby union worldwide,” said Damien Hawes, Chief Commercial Officer of HITIQ.
“We believe our technology has the potential to revolutionise how head impacts are monitored and managed in rugby, ultimately leading to safer play and better long-term health outcomes for players.”
Neurotech releases more positive data
Pediatric neurological disorders focused biotech, Neurotech (ASX: NTI), has provided further insights from its Phase II/III clinical trial aimed at Autism Spectrum Disorder (ASD).
This trial, involving 54 patients in a randomised, double-blind, placebo-controlled study, initially showed promising results earlier this year.
Now, additional analysis focused on secondary endpoints reveals significant improvements in mood and anxiety symptoms among children receiving NTI164 compared to those on a placebo.
The study used the Anxiety, Depression and Mood Scale (ADAMS), which assesses various aspects of emotional well-being in children with autism.
Results showed that over an 8-week period, NTI164 led to a notable -19.01 score improvement in the overall ADAMS scale, indicating a clinically meaningful and statistically significant reduction in symptoms.
Specifically, improvements were seen in depressed mood, social avoidance, general anxiety, and obsessive/compulsive behaviour. However, there was no significant impact observed on manic/hyperactive behaviour.
At the start of the trial, 62% of patients receiving NTI164 and 43% receiving placebo were already undergoing treatment for anxiety or depression.
By the end of the 8 weeks, those in the placebo group experienced a 24% deterioration in their ADAMS scores (+7.50), while those in the NTI164 group showed a 39% improvement (-19.9) from baseline.
These findings suggest that NTI164 holds promise as a treatment option for managing emotional symptoms associated with ASD, potentially offering significant relief for children who often struggle to communicate their emotional states effectively.
Dr Thomas Duthy, Executive Director of Neurotech said:
“Significant improvements seen in these children’s anxiety, mood and depression as measured by ADAMS is consistent with our previous findings in autism and reinforces our confidence in the utility of NTI164 as a chronically administered therapy in autism, where safe and effective therapies are urgently needed.”
Telix upgrades guidance
Meanwhile, Telix Pharma (ASX: TLX) announced today its financial results and business updates for the second quarter of 2024.
The company reported unaudited total revenue of approximately US$124 million, driven mainly by sales of its prostate cancer imaging product, Illuccix.
This marks a 55% increase compared to the same quarter last year and an 8% increase from the previous quarter.
Revenue from Illuccix sales in the United States totalled approximately US$121 million, up from US$78 million in the pcp.
Based on these strong results, Telix has revised its revenue guidance for the full year of FY24 to be between US$490 million to US$510 million.
Ghis represents a significant increase of approximately 48% to 54% compared to 2023 revenue. Previous guidance ranged from US$445 million to US$465 million.
At Stockhead we tell it like it is. While Neurotech is a Stockhead advertiser, it did not sponsor this article.
The post ASX Health Stocks: HitIQ’s mouthguard approved by World Rugby; Neurotech reports positive results appeared first on Stockhead.
